



## Change in the Management of Neurotune AG

**Schlieren, 26<sup>th</sup> January 2009.** Neurotune AG, a Swiss biopharmaceutical company, announces a change in the management. Starting March 1<sup>st</sup> 2009, Dr. Bruno Oesch will take over the position of Chief Executive Officer from Dr. Andreas J. Schulze, who joined Neurotune in 2005 and is holding the position of CEO since 2006. Andreas J. Schulze will leave at his request to take on a fresh challenge in another company shortly.

Bruno Oesch is co-founder of Prionics AG and Neurotune AG. Serving as Chairman of the Board of Directors since Neurotune's foundation in 2005 he has been significantly involved in the strategic alignment of the company.

### CONTACT

#### neurotune ag

Mrs. Nadia De Marinis  
Assistant to the CEO  
Wagistrasse 27 a  
8952 Schlieren  
Switzerland  
[www.neurotune.com](http://www.neurotune.com)  
Phone +41 44 200 21 95  
Fax +41 44 200 21 80  
[nadia.demarinis@neurotune.com](mailto:nadia.demarinis@neurotune.com)

#### Media enquiries

Dr. Holger Bengs  
Biotech Consulting  
Phone +49 69 6199 4273  
Fax +49 69 6199 4249

[info@holgerbengs.de](mailto:info@holgerbengs.de)

---

## **ABOUT NEUROTUNE AG**

Neurotune was incorporated in January 2005 and has its domicile in Schlieren, Switzerland. Neurotune develops small-molecular drugs to treat disorders of the human nervous system.

This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the Neurotune's shelf registration statement and the registered direct offering. For further information regarding these and other risks related to Neurotune's business, investors should consult Neurotune.